Trials / Withdrawn
WithdrawnNCT00584025
Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of South Florida · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | levetiracetam | 100 - 500mg IV q 15 min |
| DRUG | Placebo | Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2008-01-02
- Last updated
- 2021-11-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00584025. Inclusion in this directory is not an endorsement.